Literature DB >> 20189639

Increasing HIV prevention and care for injecting drug users.

Don C Des Jarlais1, Kamyar Arasteh, Marya Gwadz.   

Abstract

Entities:  

Mesh:

Year:  2010        PMID: 20189639      PMCID: PMC7137987          DOI: 10.1016/S0140-6736(10)60314-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
In The Lancet today, Bradley Mathers and colleagues make a heroic effort—in fact, a systematic review—to document the coverage (services provided per individual in need of services) for HIV prevention and care for injecting drug users (IDUs) throughout the world. Whilst the problems in obtaining data and in assessing the quality of data that could be obtained were formidable, two conclusions can be safely drawn. First, there is great variation in coverage of HIV-related services for IDUs across different countries; and second, in much of the world, coverage is clearly inadequate. There is considerable evidence that HIV-prevention programmes for IDUs, particularly combined programming, in which multiple programmes are provided, can be very effective in reducing injecting-related HIV transmission.2, 3 This evidence suggests that the primary global need is not for new interventions to change the behaviour of IDUs, but for effective interventions to change the behaviour of policy makers to make policies and programmes consistent with the evidence base for HIV prevention and care for IDUs. Over the past 25 years, several useful theories have been developed for changing the health behaviour of IDUs and others at high risk for HIV. It may be time to apply those theories to changing the behaviour of policy makers. The first set of theories are diffusion of innovations and social learning/modelling theories. These theories articulate how new behaviours spread through social systems and how individuals in these systems influence each other to either adopt (or resist) new behaviours.4, 5 These theories have been applied in IDU interventions developed by many different researchers and have the major advantage of often producing self-sustaining behavioural changes in the IDU community. Applying these theories to changing the behaviour of national policy makers raises interesting questions. Is the policy-making system relatively open or relatively closed to innovations? Is the policy-making system highly centralised (one decision centre) or decentralised (multiple decision centres)? Who might become the early adopters and serve as models or opinion leaders for others in the system? The answers to such questions would provide guidance about initiating system change. The second theory is contingency management. This theory comes from basic behaviourism theory.6, 7 If you want to increase the frequency with which an individual performs a specific behaviour, provide a reward when the individual completes the desired behaviour. Syringe-exchange programmes in which a drug user is given a new sterile syringe for bringing in a used and potentially contaminated syringe might be the most common example of contingency management to reduce HIV transmission. Within behaviour theory, one-for-one reinforcement is typically not the most effective schedule for behavioural change. For syringe exchange, the maximum reductions in risk behaviour seem to occur when drug users are provided with sufficient numbers of syringes to meet their own needs, and they obtain extra syringes which can then be given to peers, leading to additional social reinforcement. Syringe-exchange programmes typically have many services in addition to basic exchange, which serve as additional reinforcers. Who would provide what sort of reward to political leaders for implementing HIV services for IDUs? The reward of averting large numbers of HIV infections in IDUs is certainly important, but is not consistent with a primary principle of contingency management: that rewards should be given immediately after performance of the desired behaviour. International donors, however, could require that evidence-based services for IDUs be included in national plans to address HIV for a country to receive any HIV prevention and treatment resources. The Global Fund for AIDS, Tuberculosis and Malaria has adopted this approach, although, as shown by Mathers and colleagues, there is a need for better follow-through to ensure that appropriate resources are actually provided to IDUs, particularly for antiretroviral therapy. Needle-exchange programme Care package, including new syringes, given by syringe-exchange worker at NJCRI (New Jersey Community Research Initiative) in Newark, New Jersey, USA. The third theory is psychological framing of decisions. Framing refers to setting the psychological context within which a decision will be made.9, 10 The same person might make different decisions depending on how a question is framed. AIDS reframed the act of sharing syringes for IDUs. Before AIDS, sharing was an act of assistance and solidarity; after AIDS, sharing syringes became an act in which a fatal disease could be transmitted. Many policy makers frame HIV prevention for IDUs in terms of what appears to encourage or condone drug use, and then oppose harm-reduction programmes. Within this frame, data showing that such programmes do not lead to increased drug use have had little effect in reducing opposition. It might be more effective to frame HIV prevention for IDUs in terms of the health of the community as a whole, and that public health is fundamental to the economic wellbeing of a society. For example, the economic costs of the epidemic of severe acute respiratory syndrome in China were instrumental in convincing the Government there that it needed to address AIDS. What are we learning? Literally millions of dollars and euros have been spent on collecting data and evaluating interventions to change the HIV-related behaviours of IDUs. It is time to establish a mechanism for collecting and systematically analysing data on efforts to change policies to increase implementation of HIV programmes for IDUs. HIV continues to spread among IDUs in many different countries, and the need for scaling up prevention and treatment is urgent. Although theory-based policy-implementation interventions need to be adapted to local situations, we suggest that contingency management and framing the issue in community health-economic terms might be the most useful for immediate policy change. Long-term sustained efforts to protect the health of individuals who use both licit and illicit drugs might require that policy makers acquire a basic scientific understanding of drug use and addiction, and frame policies toward drug users within a public health and human rights perspective.
  5 in total

1.  Community attitudes toward HIV prevention for injection drug users: findings from a cross-border project in southern China and northern Vietnam.

Authors:  Theodore M Hammett; Giulia D Norton; Ryan Kling; Wei Liu; Yi Chen; Doan Ngu; Kieu Thanh Binh; Ha Viet Dong; Don C Des Jarlais
Journal:  J Urban Health       Date:  2005-09       Impact factor: 3.671

Review 2.  HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage.

Authors:  Bradley M Mathers; Louisa Degenhardt; Hammad Ali; Lucas Wiessing; Matthew Hickman; Richard P Mattick; Bronwyn Myers; Atul Ambekar; Steffanie A Strathdee
Journal:  Lancet       Date:  2010-02-26       Impact factor: 79.321

3.  Does contingency management affect motivation to change substance use?

Authors:  David M Ledgerwood; Nancy M Petry
Journal:  Drug Alcohol Depend       Date:  2005-11-28       Impact factor: 4.492

4.  Syringe exchange, injecting and intranasal drug use.

Authors:  Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Martin Ringer; Samuel R Friedman
Journal:  Addiction       Date:  2009-11-05       Impact factor: 6.526

5.  HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors.

Authors:  Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Holly Hagan; David C Perlman; Lucia V Torian; Sara Beatice; Salaam Semaan; Samuel R Friedman
Journal:  Drug Alcohol Depend       Date:  2010-02-16       Impact factor: 4.492

  5 in total
  3 in total

1.  Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?

Authors:  Dimitra Panagiotoglou; Emanuel Krebs; Jeong Eun Min; Michelle Olding; Keith Ahamad; Lianping Ti; Julio S G Montaner; Bohdan Nosyk
Journal:  Int J Drug Policy       Date:  2017-06-01

Review 2.  Translation of biomedical prevention strategies for HIV: prospects and pitfalls.

Authors:  Sten H Vermund; José A Tique; Holly M Cassell; Megan E Pask; Philip J Ciampa; Carolyn M Audet
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

3.  HIV infection among people who inject drugs: the challenge of racial/ethnic disparities.

Authors:  Don C Des Jarlais; Dennis McCarty; William A Vega; Heidi Bramson
Journal:  Am Psychol       Date:  2013 May-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.